|
|
|
|
|
15.10.25 - 04:48
|
EyePoint Announces Pricing of Public Offering (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $12.00 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 1,500,000 shares of its common stock at a price to the public of $11.999 per each pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses payable by EyePoint. All of the shares of common stock and pre-funded warrants are being so...
|
|
|
|
|
|
|
|
|
|
|
|
|
16.09.25 - 13:03
|
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
|
|
|
26.08.25 - 13:03
|
EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:...
|
|
|
18.08.25 - 22:03
|
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
06.08.25 - 13:36
|
EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET....
|
|
|
|
|
|
|
30.07.25 - 13:03
|
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments....
|
|
|
|
|
16.07.25 - 13:03
|
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
|
|
|
16.06.25 - 13:03
|
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
